Wide Ranks

BOLD

Boundless Bio, Inc.

2.52

Top Statistics
Market Cap 56 M Forward PE -0.6955 Revenue Growth 0.00 %
Current Ratio 17.03 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 1.64 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 167 M Total Cash Per Share 7.50 Total Debt 121000
Total Debt To Equity 0.0730 Current Ratio 17.03 Book Value Per Share 7.42
All Measures
Short Ratio 332.00 % Message Board Id finmb_637641859 Shares Short Prior Month 265787
Return On Equity -0.4117 City San Diego Uuid 2909dd0e-0336-310b-ada9-735b859a3d19
Previous Close 2.66 First Trade Date Epoch Utc 1 B Book Value 7.42
Total Debt 121000 Volume 130613 Price To Book 0.3397
Fifty Two Week Low 2.33 Total Cash Per Share 7.50 Shares Short Previous Month Date 1 B
Target Median Price 20.00 Max Age 86400 Sand P52 Week Change 0.3133
Target Mean Price 18.33 Net Income To Common -61059000 Short Percent Of Float 0.0124
Implied Shares Outstanding 22 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 132850 Average Volume10days 132850 Total Cash 167 M
Next Fiscal Year End 1 B Held Percent Insiders 0.1144 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 2.66
Target Low Price 14.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.13
Open 2.60 Free Cashflow -35863624 State CA
Dividend Yield 0.00 % Return On Assets -0.2697 Time Zone Short Name EST
Trailing Eps -2.74 Day Low 2.51 Address1 9880 Campus Point Drive
Shares Outstanding 22 M Price Hint 4 Target High Price 21.00
Website https://boundlessbio.com 52 Week Change -0.8232 Average Volume 69015
Forward Eps -3.67 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 1669.70 % Is_sp_500 False Regular Market Day High 2.72
Profit Margins 0.00 % Debt To Equity 0.0730 Fifty Two Week High 15.24
Day High 2.72 Shares Short 212502 Regular Market Open 2.60
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0095 Operating Cashflow -56964000 Currency USD
Time Zone Full Name America/New_York Market Cap 56 M Is_nasdaq_100 False
Zip 92121 Quote Type EQUITY Industry Biotechnology
Long Name Boundless Bio, Inc. Regular Market Day Low 2.51 Held Percent Institutions 0.7602
Current Price 2.52 Address2 Suite 120 Enterprise To Ebitda 1.64
Financial Currency USD Current Ratio 17.03 Industry Disp Biotechnology
Number Of Analyst Opinions 3 Country United States Float Shares 14 M
Two Hundred Day Average 5.74 Enterprise Value -110821624 Forward PE -0.6955
Regular Market Volume 130613 Ebitda -67748000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA.

Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers.

The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA.

Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019.

The company was incorporated in 2018 and is headquartered in San Diego, California.